MondegarAI
Birchview Capital, LP

Q3 2024 · 13F-HR/A

Birchview Capital, LPholdings as filed

Filed 2025-06-30 · accession 0001618205-25-000007

$115.5M
Reported value
61
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
110122108BMYBRISTOL-MYERS SQUIBB CO$35.5M30.7%686,182CommonSOLE
09075X108BIODESIX INC COM RST$10.1M8.76%5,696,113CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$6.2M5.33%400,400CommonSOLE
05479K106ELUTELUTIA INC$5.0M4.36%1,321,215CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP$3.6M3.10%10,000CommonSOLE
G72800108PRTAPROTHENA CORP PLC$3.5M3.04%209,574CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$3.5M3.02%30,240CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$3.4M2.97%74,000CommonSOLE
415858109HROWHARROW HEALTH INC$3.3M2.84%72,910CommonSOLE
74838J101QUIDELORTHO CORP$3.1M2.67%67,619CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$3.0M2.59%320,930CommonSOLE
05463X106AXGNAXOGEN INC$2.8M2.39%197,000CommonSOLE
71944F106PHRPHREESIA INC$2.6M2.26%114,700CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$2.6M2.23%210,000CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$2.2M1.87%48,000CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$2.1M1.79%148,000CommonSOLE
574795100MASIMASIMO CORP$2.0M1.76%15,280CommonSOLE
69047Q102OVVOVINTIV INC$2.0M1.73%52,200CommonSOLE
256086109DCGODOCGO INC$1.7M1.48%515,000CommonSOLE
14843C105CSTLCASTLE BIOSCIENCES INC$1.7M1.43%58,000CommonSOLE
G01767105ALKSALKERMES PLC$1.4M1.21%50,000CommonSOLE
26884L109EQTEQT CORPORATION$1.3M1.10%34,619CommonSOLE
02081G201ATECALPHATEC HOLDINGS INC$1.1M0.95%198,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$949,5600.82%82,000CommonSOLE
G5269C101KINIKSA PHARMACEUTICALS LTD$749,7000.65%30,000CommonSOLE
88025U109TXG10X GENOMICS INC$677,4000.59%30,000CommonSOLE
40637H109HALOHALOZYME THERAPEUTICS INC$572,4000.50%10,000CommonSOLE
00430H102ACCELERATE DIAGNOSTICS INC$556,1580.48%325,239CommonSOLE
23282W605CYTKCYTOKINETICS INC$528,0000.46%10,000CommonSOLE
45720N103INBXINHIBRX BIOSCIENCES INC$502,8430.44%32,110CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$406,4900.35%7,000CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$403,7600.35%14,000CommonSOLE
89455T109TMCITREACE MEDICAL CONCEPTS INC$396,4300.34%68,350CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$393,7000.34%10,000CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$389,9610.34%469,832CommonSOLE
19249H103CHRSCOHERUS BIOSCIENCES INC$386,8800.33%372,000CommonSOLE
04335A105ARVNARVINAS INC$369,4500.32%15,000CommonSOLE
74340E103PGNYPROGYNY INC$368,7200.32%22,000CommonSOLE
G11196105BIOHAVEN PHARMACEUTICAL HOLDING CO LTD$368,0290.32%7,365CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$359,4800.31%4,000CommonSOLE
230031106CGEMCULLINAN ONCOLOGY INC$334,8000.29%20,000CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$328,0000.28%40,000CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$320,4000.28%10,000CommonSOLE
G6674U108NVCRNOVOCURE LTD$312,6000.27%20,000CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$312,2250.27%2,500CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$304,0000.26%40,000CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$299,0400.26%28,000CommonSOLE
09627Y1092655787DBLUEPRINT MEDICINES CORP$249,7500.22%2,700CommonSOLE
98401F105XNCRXENCOR INC$247,3530.21%12,300CommonSOLE
38341P102GOSSGOSSAMER BIO INC$136,2970.12%138,176CommonSOLE
09609G100BLUEBIRD BIO INC$109,7180.10%211,200CommonSOLE
022307102ALMSALUMIS INC$106,8000.09%10,000CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$100,0000.09%10,000CommonSOLE
N90064101QUREUNIQURE NV$98,6000.09%20,000CommonSOLE
N44821101IFRXINFLARX NV$76,5000.07%50,000CommonSOLE
901384107TSVT*2SEVENTY BIO INC$74,7320.06%15,833CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$62,7840.05%28,800CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$58,8800.05%16,000CommonSOLE
12674W109CABACABALETTA BIO INC$47,2000.04%10,000CommonSOLE
690145107OMGBPOUTSET MEDICAL INC$6,7700.01%10,000CommonSOLE
71902K105CERO THERAPEUTICS HOLDINGS INC$1,2100.00%12,972CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.